A Phase 1 Healthy Volunteer Dose Escalation to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Intravenous Human IgG1 Fc-F241A (NVG-2089) for the Treatment of CIDP (P4-11.015)
To evaluate the safety, PK, and PD of NVG-2089 following single and multiple ascending doses in healthy volunteers.
Authors
- Bill Avery
- Joseph Wai-Hin Leung
- Kurt A. Grimm
- Pamela B. Conley (ORCID: https://orcid.org/0000-0001-9400-6531)
- Jessica Bright
- Sherry Mathew (ORCID: https://orcid.org/0000-0001-5689-8233)
- Alan Glicklich
- David D. Kim (ORCID: https://orcid.org/0000-0001-5605-9536)
- Anoshie Ratnayake
- Greg Coffey
- Bella Oguno
- Yvonne Coffey
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208813
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00